Roche taps Recursion's AI to find new brain disease targets

Roche is using Recursion's AI platform to identify novel drug targets for brain diseases, part of a wave of AI-driven discovery companies promising to cut the industry's failure rate in clinical trials. Neurology has among the worst attrition in drug development, making it both the hardest test and the biggest potential payoff for computational target discovery. The value of these platforms rests on whether AI-nominated targets survive trials at better rates than conventionally sourced ones, evidence that will take years to accumulate.

View full digest for August 7, 2026